Childhood cancer data initiative: clinical trial specimen molecular characterization (ctsmc) program
Active Awarded Last action
- Contract number
- 75N91020F00021
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $45,855,926
Award facts
- Contract value 100% obligated
- $45,855,926.00 Current and potential, with all options
- Completion date 61% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $3,749,767 | |
| Supplemental Agreement for work within scope | $11,249,899 | |
| Supplemental Agreement for work within scope | $3,192,111 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $5,624,623 | |
| Other Administrative Action | $17,137,213 | |
| Other Administrative Action | $904,846 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,997,467 |
Show all 12
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on September 25, 2020, under a cost-plus-fixed-fee structure with a ceiling value of $45.9 million for the Childhood Cancer Data Initiative: Clinical Trial Specimen Molecular Characterization (CTSMC) Program, with ultimate completion on August 31, 2030.
Place of performance is Frederick, MD. Leidos Biomedical Research Inc., a Federally Funded Research and Development Center (FFRDC) contractor subsidiary of Leidos Holdings, Inc., provides biomedical research and facilities support services to NCI and NIH. The order calls for molecular characterization work supporting clinical trial specimens under the childhood cancer research initiative.
Government-invoiced labor across reported fiscal years shows significant scaling: FY2021 invoiced $312 thousand across 0.4 FTEs and 836 contractor hours; FY2023 ramped to $5.8 million across 0.9 FTEs and 1,850 contractor hours; FY2024 invoiced $6.2 million across 0.5 FTEs and 1,082 contractor hours. The derived blended hourly rate rose from $373.44 in FY2021 to $5,737.07 in FY2024, reflecting increased pricing posture. In FY2024, one subcontractor absorbed 84 percent of contractor hours, indicating substantial sub-engagement depth.
Quick answers
Who was awarded contract 75N91020F00021?
75N91020F00021 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 25, 2020.
How much is contract 75N91020F00021 worth?
The government has obligated $45,855,926 on 75N91020F00021.
Is contract 75N91020F00021 an order under another contract?
Yes. 75N91020F00021 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00021 competed?
The extent of competition for 75N91020F00021 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award